Navigation Links
DAIICHI SANKYO EUROPE is Applying for Approval of its New Combination Product of Olmesartan and Amlodipin
Date:10/1/2007

MUNICH, Germany, October 1 /PRNewswire/ --

- New Product Under Development for the Treatment of High Blood Pressure

- Approval Requested in 28 European Countries

DAIICHI SANKYO EUROPE GmbH has applied in 28 European countries for approval of a new antihypertensive medication. It is a fixed combination (CS-8663) of two substances, the angiotensin receptor blocker (ARB) Olmesartan and the calcium antagonist Amlodipin.

When approved, the new combination for treatment of essential hypertension is designed for use in patients whose blood pressure cannot be adequately controlled through therapy with the respective monopreparation. In clinical trials the combination of Olmesartan / Amlodipin (CS-8663) has shown a significant lowering of blood pressure. In the new fixed combination, two complementary therapeutic approaches are combined: blocking of the angiotensin II receptor and blocking of the calcium channel. Olmesartan is already being marketed by DAIICHI SANKYO and is the angiotensin receptor blocker with the greatest sales growth in Europe(1). Amlodipin is one of the most frequently used calcium antagonists in many European countries.

"Hypertension is currently viewed as the number one cause of death. Most patients need two or even more medications to normalise their blood pressure. The new fixed combination has proved to be effective and well tolerated in a large number of patients. That also applies to patients who have very high blood pressure at the start of therapy," says Dr Petra Laeis, Head of Clinical Research at DAIICHI SANKYO EUROPE. "The combination of the two well-known agents Olmesartan and Amlodipin in one tablet gives doctors another effective treatment option for hypertension, which can lead to better results because patients are more likely to use it faithfully," continues Dr Laeis.

DAIICHI SANKYO is a worldwide, research-oriented pharmaceutical company, created through the merger of the two traditional Japanese enterprises Daiichi and Sankyo. The company is one of the world's leading manufacturers of medication. The company's research activities focus on the areas of cardiovascular, haematology, diabetes, anti-infectives and cancer. DAIICHI SANKYO has its European headquarters in Munich.

For additional information, please visit our website at

http://www.daiichi-sankyo.eu/

(1) Source: IMS MIDAS Juli 2007

Contact:

Dr Andrea Jager

Vice Director Operative Marketing

Telephone +49-(0)89-78-08-454

andrea.jaeger@daiichi-sankyo.eu


'/>"/>
SOURCE DAIICHI SANKYO EUROPE GmbH
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Development of an NK2 neuropeptide receptor binding assay using LEADseeker Multimodality Imaging System
2. Development of a CRF1 neuropeptide receptor binding assay using LEADseeker Multimodality Imaging System
3. A simple and rapid LC-MS/MS method for the simultaneous determination of nine antiretroviral drugs commonly used in Europe (protease Inhibitors and non-nucleoside reverse transcriptase inhibitors)
4. Merge launches diagnostic mammography workstation in Europe
5. Mirus granted European patent for gene therapy
6. Johnson Controls to expand in Europe
7. Innovation thrives in Europe
8. Info security group announces first Eastern European chapter
9. EMD Biosciences partners with European biotech company
10. Third Wave lands European distribution deal, reports high earnings
11. Third Wave seeks approval of Cystic Fibrosis test
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... ... 18, 2017 , ... Whitehouse Labs has furthered its efforts ... Inc. (AMRI), the scientific staff dedicated to Extractables / Leachables & Impurities has ... in 2017. Extractable & Leachable evaluations have become increasingly more vital to successful ...
(Date:1/18/2017)... ... ... from a new study are stating that if levels of the blood test called ... there is still remaining prostate cancer cells that are more likely to come back, spreading ... an indicator of whether a man’s prostate cancer is growing or not,” stated Dr. ...
(Date:1/18/2017)... ... January 18, 2017 , ... uBiome, ... latest paper by its Science Editor, Dr. Elisabeth Bik, in the December 2016 ... Dr. Bik joined uBiome in October 2016 from her previous position at Stanford ...
(Date:1/18/2017)... DIEGO , Jan. 18, 2017  HUYA Bioscience ... of China,s pharmaceutical innovations, announced ... of Sciences Innovation and Investment Company (referred to as ... commercializing biomedical innovations discovered by leading scientists at CAS ... world. HUYA is the first company to ...
Breaking Biology Technology:
(Date:12/15/2016)... DUBLIN , Dec 15, 2016 ... Research and Markets has announced ... to their offering. The report forecasts the global military ... 2016-2020. The report has been prepared based on an ... market landscape and its growth prospects over the coming years. The report ...
(Date:12/15/2016)... 14, 2016 "Increase in mobile transactions is ... mobile biometrics market is expected to grow from USD ... 2022, at a CAGR of 29.3% between 2016 and ... the growing demand for smart devices, government initiatives, and ... "Software component is expected to grow at a high ...
(Date:12/8/2016)... -- Singulex, Inc., the leader in Next Generation Immunodiagnostics powered ... and supply agreement with Thermo Fisher Scientific, the world ... to Thermo Scientific BRAHMS PCT (Procalcitonin), a biomarker which, ... diagnose systemic bacterial infection and sepsis and in ... assessing the risk of critically ill patients for progression ...
Breaking Biology News(10 mins):